Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2021-12-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
向不特定对象发行可转换公司债券中签号码公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the lottery results for the subscription of convertible bonds issued by Zhejiang Tailin Biotechnology Co., Ltd. It details the subscription process, rules for investors, underwriting arrangements, and the winning numbers for the bond subscription lottery. The content focuses on the issuance and allocation of convertible bonds to investors, which is a capital raising activity. There are no financial statements or detailed financial analysis present, and the document is relatively short (2818 characters). It is not an annual or interim report, nor an earnings release or management discussion. It is not a regulatory certification or legal proceeding. The document fits the category of a Capital/Financing Update as it provides information about the issuance and subscription results of convertible bonds, which is a financing activity.
2021-12-29 Chinese
关于控股股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by a controlling shareholder of the company. It details the number of shares pledged, the proportion of total shares, and assurances about the absence of risks related to the pledge. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledge activity, which fits the category of Capital/Financing Update (CAP) as it relates to financing activities involving share pledges by a major shareholder.
2021-12-28 Chinese
向不特定对象发行可转换公司债券网上发行中签率及优先配售结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the issuance of convertible bonds by Zhejiang Tailin Biotechnology Co., Ltd. It details the subscription results, allocation to original shareholders and public investors, subscription rates, and underwriting arrangements. The document references regulatory rules and procedures for bond issuance and subscription, but it does not contain financial statements or detailed financial analysis. It is primarily an announcement of the subscription and allocation results for a capital raising activity involving convertible bonds. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive information about the financing event itself, not just a notice of report publication or certification, so it is not RPA or RNS.
2021-12-28 Chinese
向不特定对象发行可转换公司债券发行提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the issuance of convertible bonds by Zhejiang Tailin Biological Technology Co., Ltd. It includes information about the bond issuance process, subscription dates, underwriting arrangements, regulatory approvals, and investor instructions. The content focuses on the company's capital raising activity through convertible bonds, including underwriting and subscription details. There is no financial statement data or management discussion of financial results, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or legal proceeding. The document is clearly an update on the company's financing activity, specifically the issuance of convertible bonds to unspecified investors. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2021-12-27 Chinese
第三届监事会第四次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of resolutions passed at the fourth meeting of the third Supervisory Board of Zhejiang Tailin Biotechnology Co., Ltd. It details decisions regarding the issuance of convertible bonds, including approval of the bond issuance plan, bond terms, issuance scale, interest rates, conversion price, and related procedural matters. The document includes voting results and references regulatory approvals from the China Securities Regulatory Commission. It is not a full financial report but an official announcement of corporate decisions related to capital raising and bond issuance. The document length is about 3,077 characters, which is relatively short and focused on specific financing decisions rather than comprehensive financial data or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-12-23 Chinese
第三届董事会第四次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of resolutions passed at the fourth meeting of the third board of directors of Zhejiang Tailin Biotechnology Co., Ltd. The content focuses on the approval of a convertible bond issuance plan, including details such as issuance scale, bond terms, interest rates, conversion price, and subscription arrangements. It also mentions regulatory approvals and procedural compliance. The document is an official announcement of board decisions related to financing activities, specifically the issuance of convertible bonds. It does not contain financial statements or detailed financial performance data, nor is it a transcript or presentation. The primary focus is on capital raising and financing structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is about 3100 characters, which is consistent with an announcement rather than a full report.
2021-12-23 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.